Patents by Inventor Heather Margaret Ladyman

Heather Margaret Ladyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOLOGICAL PRODUCTS
    Publication number: 20210371547
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: January 19, 2021
    Publication date: December 2, 2021
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Simon Peter TICKLE, Heather Margaret LADYMAN
  • BIOLOGICAL PRODUCTS
    Publication number: 20170145114
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Andrew George POPPLEWELL, Simon Peter TICKLE, Heather Margaret LADYMAN
  • BIOLOGICAL PRODUCTS
    Publication number: 20160326247
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: March 14, 2016
    Publication date: November 10, 2016
    Inventors: Andrew George POPPLEWELL, Simon Peter TICKLE, Heather Margaret LADYMAN
  • Biological products
    Patent number: 8895714
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Simon Peter Tickle, Heather Margaret Ladyman
  • BIOLOGICAL PRODUCTS
    Publication number: 20120302739
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the clains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 29, 2012
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • BIOLOGICAL PRODUCTS
    Publication number: 20110165659
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: March 16, 2011
    Publication date: July 7, 2011
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • Biological products
    Patent number: 7919606
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: April 5, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • BIOLOGICAL PRODUCTS
    Publication number: 20100021995
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: September 23, 2008
    Publication date: January 28, 2010
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological products
    Patent number: 7355011
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: April 8, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological products
    Publication number: 20030235869
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: May 2, 2003
    Publication date: December 25, 2003
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman